465 related articles for article (PubMed ID: 34263614)
21. Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis.
Tanabe J; Watanabe N; Endo A; Nagami T; Inagaki S; Tanabe K
Intern Med; 2021 Feb; 60(4):569-573. PubMed ID: 33028770
[TBL] [Abstract][Full Text] [Related]
22. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
24. Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: a case report.
Wakefield C; Shultz C; Patel B; Malla M
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34728505
[TBL] [Abstract][Full Text] [Related]
25. Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report.
Delombaerde D; Vervloet D; Berwouts D; Beckers R; Prenen H; Peeters M; Gremonprez F; Croes L; Vulsteke C
J Med Case Rep; 2022 Jul; 16(1):275. PubMed ID: 35831829
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
[TBL] [Abstract][Full Text] [Related]
27. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
[TBL] [Abstract][Full Text] [Related]
28. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
29. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma.
Xing Q; Zhang ZW; Lin QH; Shen LH; Wang PM; Zhang S; Fan M; Zhu B
Ann Transl Med; 2020 Mar; 8(5):250. PubMed ID: 32309397
[TBL] [Abstract][Full Text] [Related]
30. Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature.
Cuenca JA; Hanmandlu A; Wegner R; Botdorf J; Tummala S; Iliescu CA; Nates JL; Reddy DR
BMC Anesthesiol; 2023 Sep; 23(1):310. PubMed ID: 37700240
[TBL] [Abstract][Full Text] [Related]
31. Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review.
Bai J; Li D; Yang P; Xu K; Wang Y; Li Q; Liu J; Du W; Zhang F; Feng R
Front Oncol; 2021; 11():778185. PubMed ID: 35047395
[TBL] [Abstract][Full Text] [Related]
32. [Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer].
Jiang JJ; Li YQ; Gu YY
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jan; 45(1):47-52. PubMed ID: 35000305
[No Abstract] [Full Text] [Related]
33. Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review.
Liang S; Yang J; Lin Y; Li T; Zhao W; Zhao J; Dong C
Front Immunol; 2021; 12():682262. PubMed ID: 34305915
[TBL] [Abstract][Full Text] [Related]
34. Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report.
Ye Y; Li Y; Zhang S; Han G
J Int Med Res; 2022 Oct; 50(10):3000605221133259. PubMed ID: 36300305
[TBL] [Abstract][Full Text] [Related]
35. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
36. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
[TBL] [Abstract][Full Text] [Related]
37. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
Rhee JY; Torun N; Neilan TG; Guidon AC
Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
Leaver PJ; Jang HS; Vernon ST; Fernando SL
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]